Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.3%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 38,210 shares, a decrease of 14.3% from the January 29th total of 44,597 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average trading volume of 11,829 shares, the short-interest ratio is currently 3.2 days. Based on an average trading volume of 11,829 shares, the short-interest ratio is currently 3.2 days. Currently, 2.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC lifted its position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,736 shares of the company’s stock after purchasing an additional 3,945 shares during the period. Geode Capital Management LLC owned 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent quarter. Institutional investors own 27.72% of the company’s stock.

Alaunos Therapeutics Price Performance

NASDAQ:TCRT opened at $3.30 on Wednesday. The firm has a market capitalization of $7.66 million, a price-to-earnings ratio of -1.43 and a beta of -1.29. The business has a 50 day simple moving average of $2.93 and a 200-day simple moving average of $2.91. Alaunos Therapeutics has a 1 year low of $1.31 and a 1 year high of $6.20.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.